HPV vaccine

Cancer vaccine development has had many challenges. But with recent breakthroughs and new partnerships, could we be closer than ever?

Across the diverse audience of cancer researchers, health policy professionals, government officials and cancer survivors there was a common desire at the World Cancer Congress: to make up for lost time. 

From strengthening the understanding of the link between HPV and cervical cancer, to working towards reducing cervical cancer to the point where almost no one develops it, our history with this particular disease goes way back.

Focusing on cancer prevention globally is essential; we cannot say we have beaten cancer until we have beaten it everywhere.

Dr Ishu Kataria and her team are working out how to get the HPV vaccine to more than 70 million girls and help India ‘eliminate’ cervical cancer.

We spoke to Dr Ishu Kataria who works with WHO to prevent the spread of infections like HPV, which causes 99% of cervical cancers worldwide.

New results find that the HPV vaccine was shown to dramatically reduce cervical cancer rates by 90% in women in their 20s who were offered it at age 12 to 13.

We want to have a conversation about human papillomavirus (HPV), starting with 6 questions about HPV people frequently ask our Cancer Research UK nurses.

Long awaited study results have confirmed that the quadrivalent human papillomavirus (HPV) vaccine substantially reduces invasive cervical cancer risk.  

A vaccine to prevent cervical cancer is safe and effective in reducing cell changes, a new review has confirmed.